Skip to main content

Axxam Receives Two Grants Worth 7.8M Euro from Italian Government

NEW YORK, Jan. 10 (GenomeWeb News) - Axxam said today that it has received two research grants, worth a total of €7.8 million, from the Italian Research Ministry and the Regione Lombardia to advance drug-discovery projects.


The first grant, worth €6.7 million, will be awarded over a three-year period with 33 percent non-refundable and 67 percent repayable at a 0.5 percent interest rate within ten years time. The funding was granted in support of Axxam's development of advanced screening assays for high-throughput screening, as well as new screening technologies, the company said.


The second grant, worth €1.1 million, will be awarded over two years and is non-refundable, said Axxam. The financing will support a new project in the field of cell-based assays for HTS based on the innovative use of mouse stem cells.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.